Shares in Danish cannabis oil firm StenoCare to debut
Surge in investor interest in a substance that is still banned or restricted in many markets
Scientists say evidence is growing that cannabis can ease epilepsy and other conditions such as chronic pain.
Danish cannabis oil firm StenoCare will make its stock market debut on Friday, aiming to take advantage of a recent surge in investor interest in a substance that is still banned or restricted in many markets.
The company said earlier this month its initial public offering (IPO) on the Danish-Swedish Spotlight exchange was more than 20 times oversubscribed, putting it on course to raise 18.6 million Danish crowns ($2.85 million).
It plans to use the money to launch its own production facility to serve local customers and to export to other European markets.
Scientists say evidence is growing that cannabis can ease epilepsy and other conditions such as chronic pain, multiple sclerosis and chemotherapy-induced nausea, prompting renewed interest in a substance best known for its psychoactive properties.
Denmark is one of several European countries, including Germany, Britain, the Czech Republic and Italy, that have allowed prescriptions of medicinal cannabis oil.
Denmark, which legalised the medicinal use of cannabis from January 1st, is also one of the few European nations to legalise its local production as well.
Recreational use of cannabis is still prohibited in the country, however, even though the capital’s district of Christiania is famous for its cannabis-selling booths, which are rarely targeted by the authorities.
StenoCare currently imports cannabis from Canada’s CannTrust, with the first deliveries to Danish pharmacies and hospitals made last month.
Cannabis is also attracting the interest of consumer products companies.
Canada last week became only the second country in the world after Uruguay to fully legalise cannabis, with the lead up to that move prompting drinks firms such as Constellation Brands, Molson Coors and Heineken to look into cannabis-infused drinks.
StenoCare, founded last year by CEO Thomas Skovlund Schnegelsberg and chief operating officer Soren Kjaer, priced its IPO at 8.80 crowns per share, valuing the company at 59.7 million crowns. – Reuters